Cargando…

Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis

SIMPLE SUMMARY: Lung cancer is the leading cause of cancer-related death worldwide. Although novel therapy regimens using immuno- and targeted therapy have improved survival for a subgroup of patients with lung cancer, the five-year survival rate is still poor. The inhibitor of apoptosis protein (IA...

Descripción completa

Detalles Bibliográficos
Autores principales: Fung, Stephen, Knoefel, Wolfram Trudo, Krieg, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392569/
https://www.ncbi.nlm.nih.gov/pubmed/34439255
http://dx.doi.org/10.3390/cancers13164098
_version_ 1783743534151499776
author Fung, Stephen
Knoefel, Wolfram Trudo
Krieg, Andreas
author_facet Fung, Stephen
Knoefel, Wolfram Trudo
Krieg, Andreas
author_sort Fung, Stephen
collection PubMed
description SIMPLE SUMMARY: Lung cancer is the leading cause of cancer-related death worldwide. Although novel therapy regimens using immuno- and targeted therapy have improved survival for a subgroup of patients with lung cancer, the five-year survival rate is still poor. The inhibitor of apoptosis protein (IAP) family represents a heterogeneous group of anti-apoptotic proteins that are highly expressed in a variety of human malignancies. Despite conflicting results regarding the prognostic significance of IAPs, high expression of some members of this family have been extensively reported to be associated with poor prognosis in lung cancer patients. Therefore, there might be a subgroup of patients that could benefit from a targeted therapy against specific IAP family members in lung cancer. The aim of this study was to perform a meta-analysis to investigate the prognostic value of IAP family members and their association with clinicopathological features in lung cancer. ABSTRACT: Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% is non-small-cell and 15% is small-cell lung cancer. The inhibitor of apoptosis proteins (IAPs) represent a heterogeneous family of anti-apoptotic proteins, some members of which have been reported to correlate with clinical outcome in lung cancer. We screened PubMed, Web of Science, and Scopus for studies that investigated the prognostic value and clinicopathological features of IAPs in lung cancer. Forty-five eligible studies with 4428 patients assessed the expression of the IAPs survivin, XIAP, livin, and BRUCE. The pooled hazard ratio (HR) of 33 studies that analyzed overall survival (OS) revealed a positive correlation between survivin expression and poor prognosis. Seven studies displayed a strong association between survivin and disease recurrence. Two studies that assessed the expression of XIAP and livin, respectively, proved a significant relationship of these IAPs with poor OS. Meta-analyses of clinicopathological variables revealed a significant association between survivin and T stage, UICC stage, the presence of lymph node metastasis, and grade of differentiation. In conclusion, high expression of distinct IAPs significantly correlates with prognosis in lung cancer. Therefore, lung cancer patients might benefit from a targeted therapy against specific IAPs.
format Online
Article
Text
id pubmed-8392569
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83925692021-08-28 Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis Fung, Stephen Knoefel, Wolfram Trudo Krieg, Andreas Cancers (Basel) Systematic Review SIMPLE SUMMARY: Lung cancer is the leading cause of cancer-related death worldwide. Although novel therapy regimens using immuno- and targeted therapy have improved survival for a subgroup of patients with lung cancer, the five-year survival rate is still poor. The inhibitor of apoptosis protein (IAP) family represents a heterogeneous group of anti-apoptotic proteins that are highly expressed in a variety of human malignancies. Despite conflicting results regarding the prognostic significance of IAPs, high expression of some members of this family have been extensively reported to be associated with poor prognosis in lung cancer patients. Therefore, there might be a subgroup of patients that could benefit from a targeted therapy against specific IAP family members in lung cancer. The aim of this study was to perform a meta-analysis to investigate the prognostic value of IAP family members and their association with clinicopathological features in lung cancer. ABSTRACT: Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% is non-small-cell and 15% is small-cell lung cancer. The inhibitor of apoptosis proteins (IAPs) represent a heterogeneous family of anti-apoptotic proteins, some members of which have been reported to correlate with clinical outcome in lung cancer. We screened PubMed, Web of Science, and Scopus for studies that investigated the prognostic value and clinicopathological features of IAPs in lung cancer. Forty-five eligible studies with 4428 patients assessed the expression of the IAPs survivin, XIAP, livin, and BRUCE. The pooled hazard ratio (HR) of 33 studies that analyzed overall survival (OS) revealed a positive correlation between survivin expression and poor prognosis. Seven studies displayed a strong association between survivin and disease recurrence. Two studies that assessed the expression of XIAP and livin, respectively, proved a significant relationship of these IAPs with poor OS. Meta-analyses of clinicopathological variables revealed a significant association between survivin and T stage, UICC stage, the presence of lymph node metastasis, and grade of differentiation. In conclusion, high expression of distinct IAPs significantly correlates with prognosis in lung cancer. Therefore, lung cancer patients might benefit from a targeted therapy against specific IAPs. MDPI 2021-08-14 /pmc/articles/PMC8392569/ /pubmed/34439255 http://dx.doi.org/10.3390/cancers13164098 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Fung, Stephen
Knoefel, Wolfram Trudo
Krieg, Andreas
Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis
title Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis
title_full Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis
title_fullStr Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis
title_full_unstemmed Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis
title_short Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis
title_sort clinicopathological and prognostic significance of inhibitor of apoptosis protein (iap) family members in lung cancer: a meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392569/
https://www.ncbi.nlm.nih.gov/pubmed/34439255
http://dx.doi.org/10.3390/cancers13164098
work_keys_str_mv AT fungstephen clinicopathologicalandprognosticsignificanceofinhibitorofapoptosisproteiniapfamilymembersinlungcancerametaanalysis
AT knoefelwolframtrudo clinicopathologicalandprognosticsignificanceofinhibitorofapoptosisproteiniapfamilymembersinlungcancerametaanalysis
AT kriegandreas clinicopathologicalandprognosticsignificanceofinhibitorofapoptosisproteiniapfamilymembersinlungcancerametaanalysis